Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. CYH
CYH logo

CYH Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Community Health Systems Inc (CYH) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
3.250
1 Day change
2.69%
52 Week Range
4.460
Analysis Updated At
2026/04/17
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Community Health Systems Inc (CYH) is not a strong buy for a beginner investor with a long-term focus at this time. The stock's recent financial performance shows significant declines in revenue, net income, and EPS, which are critical indicators of company health. Additionally, while technical indicators are neutral and options data suggests mixed sentiment, there are no significant positive catalysts or strong trading signals to justify immediate investment. Given the user's impatience and unwillingness to wait for optimal entry points, holding off on this investment is recommended.

Technical Analysis

The MACD is slightly positive at 0.0308, indicating mild bullish momentum, but it is contracting. RSI at 61.797 is in the neutral zone, suggesting no clear overbought or oversold conditions. Moving averages are converging, showing no strong trend. Key support and resistance levels are close to the current price, with support at 2.938 and resistance at 3.174.

Options Data

Bullish
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
6
Buy
5

Positive Catalysts

  • The healthcare sector is generally well-positioned due to strong demand trends, favorable reimbursement policies, and benefits from AI/automation. Gross margin increased YoY by 2.00%, indicating some operational efficiency improvements.

Neutral/Negative Catalysts

  • Significant declines in revenue (-4.87% YoY), net income (-257.14% YoY), and EPS (-252.83% YoY) in the latest quarter. Analysts have lowered price targets, and there is no recent news or events to drive positive sentiment. Options data shows a higher put-call volume ratio, indicating bearish sentiment.

Financial Performance

In Q4 2025, revenue dropped to $3.106 billion (-4.87% YoY), net income fell to $110 million (-257.14% YoY), and EPS dropped to 0.81 (-252.83% YoY). Gross margin increased to 82.13 (+2.00% YoY), but overall financial performance was weak.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Truist recently lowered the price target to $3.50 from $4, maintaining a Hold rating. UBS raised the price target slightly to $3.70 from $3.60 with a Neutral rating. Analysts are generally cautious about the stock, reflecting mixed to neutral sentiment.

Wall Street analysts forecast CYH stock price to rise
3 Analyst Rating
Wall Street analysts forecast CYH stock price to rise
1 Buy
1 Hold
1 Sell
Hold
Current: 3.160
sliders
Low
2
Averages
3.67
High
5
Current: 3.160
sliders
Low
2
Averages
3.67
High
5
Truist
Hold
downgrade
$4
AI Analysis
2026-04-13
Reason
Truist
Price Target
$4
AI Analysis
2026-04-13
downgrade
Hold
Reason
Truist lowered the firm's price target on Community Health to $3.50 from $4 and keeps a Hold rating on the shares as part of a broader research note previewing Q1 results in Healthcare Services, or HC. The firm remains broadly bullish on its HC Services coverage universe tied to continued strong demand trends, overarching secular tailwinds and more favorable/stable reimbursement backdrop, with the recent Final Medicare Advantage Rule seen as an "encouraging data point", the analyst tells investors in a research note. Truist adds that it continues to think the sector is well positioned given that it's scaled, domestic and defensive, also noting that the group is a beneficiary of AI/automation/interconnectivity, with strong free cash flow and attractive financial flexibility supporting the ongoing growth investment/M&A/shareholder friendly initiatives.
UBS
Neutral
maintain
2026-02-20
Reason
UBS
Price Target
2026-02-20
maintain
Neutral
Reason
UBS raised the firm's price target on Community Health to $3.70 from $3.60 and keeps a Neutral rating on the shares.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for CYH
Unlock Now

People Also Watch